(Q43188148)

15 November 2017

Late relapse of acute myeloid leukemia with mutated NPM1 after eight years: evidence of NPM1 mutation stability (English)

1 reference

15 November 2017

1 reference

acute myeloid leukemia

1 reference

5

Robin Foa

1 reference

15 November 2017

Giovanna Meloni

1

1 reference

15 November 2017

Marco Mancini

2

1 reference

15 November 2017

Valentina Gianfelici

3

1 reference

15 November 2017

Maria Paola Martelli

4

1 reference

15 November 2017

Brunangelo Falini

6

1 reference

15 November 2017

language of work or name

1 reference

1 February 2009

1 reference

15 November 2017

1 reference

15 November 2017

94

1 reference

15 November 2017

2

1 reference

15 November 2017

298-300

1 reference

Mutations and treatment outcome in cytogenetically normal acute myeloid leukemia

15 November 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2635402

Distinctive microRNA signature of acute myeloid leukemia bearing cytoplasmic mutated nucleophosmin

25 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2635402

The impact of FLT3 internal tandem duplication mutant level, number, size, and interaction with NPM1 mutations in a large cohort of young adult patients with acute myeloid leukemia

25 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2635402

Acute myeloid leukemia carrying cytoplasmic/mutated nucleophosmin (NPMc+ AML): biologic and clinical features

25 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2635402

Cytoplasmic nucleophosmin in acute myelogenous leukemia with a normal karyotype

25 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2635402

A one-mutation mathematical model can explain the age incidence of acute myeloid leukemia with mutated nucleophosmin (NPM1).

25 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2635402

Characteristics and outcomes of acute myelogenous leukemia patients with very late relapse (>5 years).

15 August 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2635402

Nucleophosmin mutations in de novo acute myeloid leukemia: the age-dependent incidences and the stability during disease evolution

15 August 2018

1 reference

12 December 2020

Cytoplasmic nucleophosmin in myeloid sarcoma occurring 20 years after diagnosis of acute myeloid leukaemia

1 reference

12 December 2020

Immunohistochemistry predicts nucleophosmin (NPM) mutations in acute myeloid leukemia

1 reference

12 December 2020

NPM1 mutations are more stable than FLT3 mutations during the course of disease in patients with acute myeloid leukemia

1 reference

12 December 2020

Cytoplasmic mutated nucleophosmin is stable in primary leukemic cells and in a xenotransplant model of NPMc+ acute myeloid leukemia in SCID mice

1 reference

12 December 2020

Identifiers

DOI

10.3324/HAEMATOL.000059

1 reference

release_gaahbrofvvfqfc5eze56gxpdl4

15 November 2017

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/gaahbrofvvfqfc5eze56gxpdl4

24 November 2022

mapped directly with Wikidata item

1 reference

15 November 2017

PubMed publication ID

19181793

1 reference